Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (387)	4/25/1998 12:37:00 AM
From: BDR	Read Replies (1) \| Respond to of 1016

<<First you say "In my practice there is almost zero interest in MUSE" in your introduction to this thread. But now you say "a majority of the patients requesting Viagra in my practice are current MUSE users".>> There really is no contradiction here. By current MUSE users I mean people who last were using MUSE in an attempt to overcome impotence. For example, there is the guy I saw today who last got a MUSE prescription in December at 1000 mcgm. I had not seen him since because it didn't work and after several tries he gave up. He is a MUSE user (not a satisfied one) that is going to try Viagra. There were others who have been successful with MUSE in the past who were in today also asking for Viagra. They are being given samples of five 50 mg tablets so I ought to be able to tell soon if there are requests for refills. Will keep you posted. If there are a lot of upset patients because Viagra doesn't matchup to the hype I may even be a VVUS buyer.(g)

To: BDR who wrote (387)	4/27/1998 11:56:00 AM
From: Don Dunlap	Respond to of 1016

Well, Mr. Fayemi was only 1000% off his target price. Almost 2000% excluding the recent runup. Interesting that the post says he was with Wheat First. That means three brokerages within two? years Wheat First, Genesis Merchant and now Cruttendon Roth. Someone else asked about Caverject refills. I remember seeing somewhere that Caverject had sales of 60 million. I don't remember where. If true, we could hopefully draw a parallel in that Caverject kept a niche when Muse came on the market, and hopefully Muse will keeps its niche with Viagra on the market.